Drug Profile
Research programme: antibacterial therapeutics - Integrated BioTherapeutics
Alternative Names: Cd-ISTAbLatest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Integrated BioTherapeutics
- Class Antibodies; Vaccines
- Mechanism of Action Cell wall inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 14 Aug 2019 Preclinical trials in Bacterial infections in USA (unspecified route)
- 29 Jun 2016 Early research in Bacterial infections in USA (unspecified route) (Integrated BioTherapeutics pipeline, June 2016)